Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:36:23.042Z.
Calculation as of: 2026-10-06T15:36:23.042Z.
Quote observation: 2026-10-06T15:34:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4140271b5ba2e17517ffa776ba39ee0784cb590c71b20d0313403f3757235181
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.15B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15B
EBITDA Yield
12.12%
TTM Avg
13.63%
3Y Avg
7.88%
5Y Avg
6.04%
Market Cap
$1.21B
EBITDA Yield
7.02%
TTM Avg
3.73%
3Y Avg
2.86%
5Y Avg
4.37%
Market Cap
$1.13B
EBITDA Yield
11.23%
TTM Avg
12.87%
3Y Avg
11.35%
5Y Avg
9.45%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.17B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.17B | N/A | 11.26% | 11.26% | 8.77% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 12.12% | 13.63% | 7.88% | 6.04% |
| OPKO Health, Inc. (OPK)vs › | $1.14B | N/A | 7.38% | 6.98% | 5.84% |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 7.02% | 3.73% | 2.86% | 4.37% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 11.23% | 12.87% | 11.35% | 9.45% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | N/A | 2.54% | 1.69% | 1.63% |
| MannKind Corporation (MNKD)vs › | $1.22B | 1.91% | 3.43% | 3.63% | 3.63% |
| Omada Health (OMDA)vs › | $1.22B | 0.69% | 0.59% | 0.59% | 0.59% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
